AXLA's Business Model
Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence; and AXA1125 that is in Phase 2b clinical trial for treating non-alcoholic steatohepatitis, as well as in Phase 2a clinical trial for Long COVID therapy for patients. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.
| Sector & Industry | Healthcare / Biotechnology |
| Website | https://www.axcellahealth.com |
| CEO (Chief Executive Officer) | Craig R. Jalbert CIRA |
| Number of Employees | |
| IPO date | May 9, 2019 |
AXLA Latest News
|
|
|
|
|
|
|
|
|
|
| Contact | |
|---|---|
| Country | US |
| Address | 840 Memorial Drive |
| City | Cambridge |
| State | MA |
| Phone | 857 320 2200 |
| Zip Code | 02139 |
| Other Identifiers | |
| CIK | 0001633070 |
| ISIN | US05454B2043 |
| CUSIP | 05454B105 |
| Open | 0.36 |
| Previous Close | 4.58 |
| Volume | 6.78 Thou. |
| Average Volume | 0 |
| Day’s Range | 0.36 – 4.58 |
| 52 Week Range | 4.58-4.58 |
| MA (50) | 0 |
| MA (200) | 0 |
| Market Cap | 12.5 Mil. |
| Shares Out. | 2.73 Mil. |
| Earnings Date | May 02, 2024 |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
